Cabergoline as treatment of ovarian hyperstimulation syndrome: a review

被引：14
作者：
Kalampokas, Theodoros [1 ]
Creatsas, George [1 ]
Kalampokas, Emmanouil [1 ]
机构：
[1] Univ Athens, Aretaie Hosp, Dept Obstet & Gynecol 2, Athens 11526, Greece
来源：
GYNECOLOGICAL ENDOCRINOLOGY | 2013年 / 29卷 / 02期
关键词：
Cabergoline; OHSS; infertility; IVF; ENDOTHELIAL GROWTH-FACTOR; DOPAMINE AGONIST CABERGOLINE; VALVULAR HEART-DISEASE; VASCULAR-PERMEABILITY; SYNDROME OHSS; FACTOR VEGF; STIMULATION; RISK; ANGIOGENESIS; PATHOGENESIS;
D O I：
10.3109/09513590.2012.730578
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
One of the most serious complications of assisted reproduction techniques is ovarian hyperstimulation syndrome (OHSS). OHSS not only increases morbidity and mortality in IFV cycles, but also causes significant other problems, as cancelled in vitro fertilization (IVF) cycles, prolonged hospitalization, causing emotional and sociofinancial consequences. Several treatments for OHSS have been proposed and among these Cabergoline (Cb2). Despite the above-mentioned beneficial effect, Cb2 has not been widely used in everyday's clinical practice. With our study, we try to review all studies with strong evidence examining Cb2 use for OHSS prevention.
引用
收藏
页码：98 / 100
页数：3
相关论文
共 39 条
[1]   Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment:: a pilot study [J].
Alvarez, Claudio ;
Alonso-Muriel, Isabel ;
Garcia, Gabriela ;
Crespo, Juana ;
Bellver, Jose ;
Simon, Carlos ;
Pellicer, Antonio .
HUMAN REPRODUCTION, 2007, 22 (12) :3210-3214
[2]   Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction [J].
Alvarez, Claudio ;
Marti-Bonmati, Luis ;
Novella-Maestre, Edurne ;
Sanz, Roberto ;
Gomez, Raul ;
Fernandez-Sanchez, Manuel ;
Simon, Carlos ;
Pellicer, Antonio .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (08) :2931-2937
[3]   SEVERE OVARIAN HYPERSTIMULATION SYNDROME IN ASSISTED REPRODUCTIVE TECHNOLOGY - DEFINITION OF HIGH-RISK GROUPS [J].
ASCH, RH ;
LI, HP ;
BALMACEDA, JP ;
WECKSTEIN, LN ;
STONE, SC .
HUMAN REPRODUCTION, 1991, 6 (10) :1395-1399
[4]   High dose cabergoline in management of ovarian hyperstimulation syndrome [J].
Ata, Baris ;
Seyhan, Ayse ;
Orhaner, Serbulent ;
Urman, Bulent .
FERTILITY AND STERILITY, 2009, 92 (03) :1168.e1-1168.e4
[5]   Peripheral arterial vasodilation hypothesis:: a new insight into the pathogenesis of ovarian hyperstimulation syndrome [J].
Balasch, J ;
Fábregues, F ;
Arroyo, V .
HUMAN REPRODUCTION, 1998, 13 (10) :2718-2730
[6]   Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study [J].
Carizza, Carlos ;
Abdelmassih, Vicente ;
Abdelmassih, Soraya ;
Ravizzini, Pedro ;
Salgueiro, Lister ;
Salgueiro, Paulo Tudech ;
Jine, Lin Tao ;
Nagy, Peter ;
Abdelmassih, Roger .
REPRODUCTIVE BIOMEDICINE ONLINE, 2008, 17 (06) :751-755
[7]   Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review [J].
Delvigne, A ;
Rozenberg, S .
HUMAN REPRODUCTION UPDATE, 2002, 8 (06) :559-577
[8]   THE FMS-LIKE TYROSINE KINASE, A RECEPTOR FOR VASCULAR ENDOTHELIAL GROWTH-FACTOR [J].
DEVRIES, C ;
ESCOBEDO, JA ;
UENO, H ;
HOUCK, K ;
FERRARA, N ;
WILLIAMS, LT .
SCIENCE, 1992, 255 (5047) :989-991
[9]   Assisted reproductive technology in Europe, 2002. Results generated from European registers by ESHRE [J].
不详 .
HUMAN REPRODUCTION, 2006, 21 (07) :1680-1697
[10]   The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study [J].
Engmann, Lawrence ;
DiLuigi, Andrea ;
Schmidt, David ;
Nulsen, John ;
Maier, Donald ;
Benadiva, Claudio .
FERTILITY AND STERILITY, 2008, 89 (01) :84-91
1234